



## XPHYTO TO PRESENT AT LD MICRO MAIN EVENT

Vancouver, Canada (December 11, 2020) - [XPhyto Therapeutics Corp.](#) (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), announces that the Company will present at the virtual LD Micro Main Event (XIII) taking place December 14-15, 2020.

Hugh Rogers, CEO and Director of XPhyto, is scheduled to host a virtual presentation as follows:

### LD Micro Main Event (XIII)

Date: **Tuesday, December 15th**

Time: **1:20 p.m. Eastern time (10:20 a.m. Pacific time) in Track 6**

Webcast: <https://ve.mysequire.com/>

A live audio webcast and archive of the event presentation will be available using the webcast link above. For more information on the LD Micro Main Event please contact your LD Micro representative.

### Recent Company Highlights

- [XPhyto Announces RT-PCR Test For Point-Of-Care COVID-19 Detection](#)
- [XPhyto Engages German Partner For Development Of Psilocybin API Production](#)
- [XPhyto Appoints European Healthcare Executive To Board Of Directors](#)
- [Exclusive Psychedelic Drug Development Agreement Secured](#)

### About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe and is currently focused on regulatory approval and commercialization of medical products for European markets.

### XPhyto Therapeutics Corp.:

Hugh Rogers, CEO and Director

### Investor Inquiries:

Mr. Knox Henderson

T: 604-551-2360

E: [info@xphyto.com](mailto:info@xphyto.com)



[www.xphyto.com](http://www.xphyto.com)

**Media Inquiries:**

MC Services AG

Julia Hofmann, Andreas Jungfer

T: +49 89 210 228 0

E: [xphyto@mc-services.eu](mailto:xphyto@mc-services.eu)

**Forward looking statements**

This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis or psychedelic company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.